View in EDS

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.

Saved in:
Bibliographic Details
Title: Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.
Authors: Kenny HA; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Ip CKM; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Kelliher L; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Samantaray T; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Kordylewicz K; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Hoffmann R; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Rauch S; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois., Malacrida B; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Skingsley SLP; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Balkwill FR; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Battistini C; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy., Cavallaro U; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy., Wiedemeyer WR; AbbVie Inc., North Chicago, Illinois., Lengyel E; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 Aug 01; Vol. 24 (8), pp. 1252-1264.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40293279
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kenny+HA%22">Kenny HA</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Ip+CKM%22">Ip CKM</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Kelliher+L%22">Kelliher L</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Samantaray+T%22">Samantaray T</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Kordylewicz+K%22">Kordylewicz K</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Hoffmann+R%22">Hoffmann R</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Rauch+S%22">Rauch S</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Malacrida+B%22">Malacrida B</searchLink>; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Skingsley+SLP%22">Skingsley SLP</searchLink>; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Balkwill+FR%22">Balkwill FR</searchLink>; Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Battistini+C%22">Battistini C</searchLink>; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Cavallaro+U%22">Cavallaro U</searchLink>; Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Wiedemeyer+WR%22">Wiedemeyer WR</searchLink>; AbbVie Inc., North Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Lengyel+E%22">Lengyel E</searchLink>; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, Illinois.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2025 Aug 01; Vol. 24 (8), pp. 1252-1264.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40293279
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-23-0863
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1252
    Titles:
      – TitleFull: Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kenny HA
      – PersonEntity:
          Name:
            NameFull: Ip CKM
      – PersonEntity:
          Name:
            NameFull: Kelliher L
      – PersonEntity:
          Name:
            NameFull: Samantaray T
      – PersonEntity:
          Name:
            NameFull: Kordylewicz K
      – PersonEntity:
          Name:
            NameFull: Hoffmann R
      – PersonEntity:
          Name:
            NameFull: Rauch S
      – PersonEntity:
          Name:
            NameFull: Malacrida B
      – PersonEntity:
          Name:
            NameFull: Skingsley SLP
      – PersonEntity:
          Name:
            NameFull: Balkwill FR
      – PersonEntity:
          Name:
            NameFull: Battistini C
      – PersonEntity:
          Name:
            NameFull: Cavallaro U
      – PersonEntity:
          Name:
            NameFull: Wiedemeyer WR
      – PersonEntity:
          Name:
            NameFull: Lengyel E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2025 Aug 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1